Table 3.

Lists some examples of potential antiviral therapies against Hantavirus.

Antiviral therapy	Type	Function	Target	Disease	References
Lactoferrin	Lactoferrin	Block viral entry	Viral GP	HFRS	Murphy et al. (2000, 2001)
Ribavirin	Nucleoside analogs	Inhibit viral replication	RdRp	HCPS and HFRS	Chung et al. (2013) and Ogg et al. (2013)
Favipiravir	Pyrazine derivatives	Block viral entry	RdRp	HCPS	Safronetz et al. (2013)
Vandetanib	Tyrosine kinase inhibitor	Improve vascular function	VEGF/Vascular function	HCPS	Bird et al. (2016)
ETAR	Nucleoside analog	Inhibit viral entry	RdRp	HCPS and HFRS	Chung et al. (2008)
Corticosteroids	Hormone	Rebuild immune homeostasis	Immunotherapy	HCPS and HFRS	Vial et al. (2013) and Brocato and Hooper (2019)
Human Immune Sera	Human pAbs	Block viral entry	Viral GP	HCPS	Vial et al. (2015)
JL16 and MIB22	Human mAbs	Block viral entry	Viral GP	HCPS	Garrido et al. (2018)
Domain III and stem peptides	Peptides	Block viral entry	Gc glycoprotein	HCPS and HFRS	Barriga et al. (2016)
CLVRNLAWC and CQATTARNC	Cyclic nonapeptides	Block viral entry	Host receptor	HCPS	Hall et al. (2008)
Icatibant	Small molecule	Improve vascular function	BK type 2 receptor	HFRS	Antonen et al. (2013) and Laine et al. (2015)
TNF-α	Small proteins/Pro- inflammatory cytokines	Increase systemic toxicity	Vascular function	HCPS and HFRS	Vilcek (1991), Sundstrom et al. (2001) and Maes et al. (2004)
RANTES/IP- 10/MCP-1	Small proteins/Pro-inflammatory chemokines	Immunomodu lators/Inhibit viral infection	Microvascular endothelium	HFRS	Sundstrom et al. (2001) and Glass et al. (2003)